A very impressive study for how we could prevent lung cancer more than 5 years before it is diagnosed. Using machine learning, discovery of a 14-plasma protein signature of risk that predicts responsiveness to an antibody therapy to interleukin, IL-1β
Validated across 8 cohorts
@CellCellPress@CharlesSwanton
https://t.co/qpPtgs1dH0
• Platform generalization across T-DM1, T-DXd, trastuzumab and enfortumab vedotin establishes that the determining variable is payload pharmacology rather than target or conjugate chemistry.
Amazing A. Detappe! Liposomal nanoformulations, ultrasmall gadolinium-based nanoparticles & polymer-nanoparticle hydrogel are being developed to enable at-home administration of hospital-restricted biologics. Efforts to shorten the path from bench chemistry to patient benefit.
New in @NatRevBioeng w/ @FAndreMD
: No targeted nanomedicines approved despite preclinical tumor accumulation. Our thesis: It's not poor delivery, it's static formulations in a dynamic disease. Time to test adaptive nanomedicine. Thanks
@ChristineHorejs!
https://t.co/5oUw0dlfwT
Our latest paper in @ACSNano is out! 🤩
We built tiny peptide-based “delivery vehicles” that bring heavy metals (Gd, Bi, Hf) to tumors so we can fairly compare how well each one boosts external radiotherapy and radioligand therapies.
Big congrats to Dr. Sebastian and our amazing collaborators for making this happen 🙌
If you’re interested in smarter radioenhancers and “see & treat” oncology, check out the paper:
🔗 https://t.co/AkISNvLZvz
Thank you @le_Parisien@leparisien_94 for being with us at @GustaveRoussy on this special day. It’s not just about a new building, but about pushing research forward and giving more hope to patients.
📰 « Les patients attendent beaucoup de nous » : face au cancer, @GustaveRoussy offre un écrin tout neuf à ses chercheurs.
Les Prs Fabrice @barlesi et @FAndreMD rappellent l’ambition de l’institut dans @le_Parisien ⤵
https://t.co/tvsmxM1Enb